IRIS
SOTO PARRA, HECTOR
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.876
AS - Asia 966
EU - Europa 829
SA - Sud America 288
AF - Africa 96
OC - Oceania 4
Totale 5.059
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.830
SG - Singapore 667
IE - Irlanda 320
BR - Brasile 262
CN - Cina 152
RU - Federazione Russa 119
IT - Italia 97
BE - Belgio 92
CI - Costa d'Avorio 50
DE - Germania 36
UA - Ucraina 35
IN - India 33
CA - Canada 31
FR - Francia 27
VN - Vietnam 27
GB - Regno Unito 26
NG - Nigeria 23
KR - Corea 19
AT - Austria 14
IR - Iran 11
IQ - Iraq 9
TR - Turchia 9
HK - Hong Kong 8
PL - Polonia 8
AR - Argentina 7
CH - Svizzera 7
BG - Bulgaria 6
FI - Finlandia 6
MX - Messico 6
NL - Olanda 6
SE - Svezia 6
UZ - Uzbekistan 6
EC - Ecuador 5
MA - Marocco 5
SN - Senegal 5
VE - Venezuela 5
CO - Colombia 4
EG - Egitto 4
JP - Giappone 4
BD - Bangladesh 3
CZ - Repubblica Ceca 3
ES - Italia 3
ID - Indonesia 3
KE - Kenya 3
LB - Libano 3
MK - Macedonia 3
PE - Perù 3
ZA - Sudafrica 3
AL - Albania 2
AU - Australia 2
CR - Costa Rica 2
DK - Danimarca 2
HU - Ungheria 2
LT - Lituania 2
NI - Nicaragua 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PH - Filippine 2
PK - Pakistan 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BT - Bhutan 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GL - Groenlandia 1
GR - Grecia 1
HR - Croazia 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LY - Libia 1
NP - Nepal 1
PR - Porto Rico 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
Totale 5.059
Salva come PNG Salva come JPEG
Città #
Santa Clara 677
Dallas 432
Chandler 343
Singapore 330
Dublin 315
Chicago 213
Boardman 116
Brussels 92
Cambridge 88
Lawrence 88
Andover 83
Ashburn 67
Beijing 64
Des Moines 59
Abidjan 50
Catania 39
The Dalles 37
Hefei 33
Columbus 28
Wilmington 27
São Paulo 26
Houston 23
Abuja 22
Bremen 22
Jacksonville 22
Los Angeles 21
Seoul 19
Saint Petersburg 17
Ho Chi Minh City 15
Civitanova Marche 12
Leawood 11
Toronto 11
Falls Church 10
Kochi 10
Council Bluffs 9
Ottawa 9
Rio de Janeiro 9
Hong Kong 8
Mumbai 7
Ardabil 6
Curitiba 6
Milan 6
Pune 6
Rome 6
San Mateo 6
Seattle 6
Dakar 5
Guarulhos 5
Lappeenranta 5
Mexico City 5
Nanjing 5
New York 5
Nuremberg 5
Shenyang 5
Vienna 5
Aci Catena 4
Atlanta 4
Baghdad 4
Bauru 4
Boston 4
Brooklyn 4
Bussero 4
Campinas 4
Hanoi 4
Istanbul 4
Montreal 4
Moscow 4
Phoenix 4
Porto Alegre 4
Sofia 4
Stockholm 4
Tappahannock 4
Warsaw 4
Aracaju 3
Augusta 3
Belo Horizonte 3
Brasília 3
Cairo 3
Caruaru 3
Edinburgh 3
Jakarta 3
Portland 3
Poços de Caldas 3
Salvador 3
San Francisco 3
Sorocaba 3
Suzano 3
São Luís 3
Zurich 3
Auckland 2
Barbacena 2
Budapest 2
Calgary 2
Copenhagen 2
Den Haag 2
Fairfield 2
Goiânia 2
Governador Valadares 2
Gravina di Catania 2
Guayaquil 2
Totale 3.693
Salva come PNG Salva come JPEG
Nome #
Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC 101
Direct Left Ventricular Metastasis Reduction: 3D-Echo Monitoring For Management of Clinical Case 90
Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions 87
Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles 86
Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients 83
Benign form of Myasthenia Gravis after Nivolumab treatment 77
Cytoreductive surgery and hyperthermic intrapleural chemotherapy for malignant pleural diseases: Preliminary experience 76
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial 76
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma 75
Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer 74
Nutritional support in patients with cancer of the esophagus: Impact on nutritional status, patient compliance to therapy, and survival 73
Combined regimen of cisplatin, doxorubicin, and α-2b interferon in the treatment of advanced malignant pleural mesothelioma: A phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP) 73
Benign form of myasthenia gravis after nivolumab treatment 72
Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-smal-cell lung cancer 72
Ceritinib in the treatment of an adult patient with advanced neuroblastoma positive to the somatic activating mutation of ALK F1174L 72
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer 69
Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: A retrospective Italian study 68
Bladder Cancer 67
Pre-operative hyperfractionated radiotherapy and 5-Fluorouracil continuous infusion in elderly patients with locally advanced primary rectal cancer (LA-PRC): feasibility, pathologic complete response, sphincter preservation and local control 65
A summary of the Milan experience with multimodality therapies in patients with small cell lung cancer: attempts to improve long-term outcome 65
Early Gastrointestinal Progression to Immunotherapy in Lung Cancer: A Report of Two Cases 65
Pleurectomy/decortication and hyperthermic intrapleural chemotherapy for malignant pleural mesothelioma: Initial experience 64
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer 63
Ifosfamide and vinorelbine: An active regimen for patients with relapsed or refractory Hodgkin's disease 63
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma 63
Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: Result of a dose-intensity study 63
Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma 63
Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial 62
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S 62
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer 61
Treatment perspectives in advanced non-small cell lung cancer 59
Malignant pleural mesothelioma: The gemcitabine-vinorelbine combination in pemetrexed-pretreated patients 59
Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study 59
Phase ii prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy 58
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer 57
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 57
Prospective study of high-dose chemotherapy and autologous peripheral stem cell transplantation in adult patients with advanced desmoplastic small round-cell tumour 57
High-dose chemotherapy in poor-prognosis adult small round-cell tumors: Clinical and molecular results from a prospective study 57
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial 57
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 57
Valutazione economica in base allo studio NAVoTRIAL01 con riferimento al contesto sanitario italiano: Vinorelbine orale e Cisplatino o Pemetrexed e Cisplatino seguiti da mantenimento rispettivamente con Vinorelbine orale e Pemetrexed nel trattamento del Carcinoma Polmonare Non a Piccole Cellule Non Squamoso (NS-NSCLC) in stadio avanzato 56
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC 56
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC) 56
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 56
Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study 56
First-line lorlatinib or crizotinib in advanced alk-positive lung cancer 56
Women with synchronous or metachronous lung and ovarian cancer: A multi-institutional report 56
ROC Analysis Identifies Baseline and Dynamic NLR and dNLR Cut-Offs to Predict ICI Outcome in 402 Advanced NSCLC Patients 56
Uncommon manifestations of common malignancies - Case 1. Soft-tissue metastases from malignant pleural mesothelioma 55
Extensive experience of disease control with gefitinib and the role of prognostic markers 55
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 55
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study) 55
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions 54
Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study 54
Histology-based combination induction chemotherapy for elderly patients with clinical stage III non-small cell lung cancer 53
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study 52
Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma 52
Lessons from the ‘iressa’ expanded access programme: Gefitinib in special non-small-cell lung cancer patient populations 52
Epicure: A European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy 51
Non-small-cell lung cancer patients unsuitable for first-line chemotherapy: A new category of patients for clinical studies? 50
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients 50
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida) 50
Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer 50
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer 48
Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC 48
Lack of response to imatinib mesylate as second-line therapy in a patient with c-kit positive metastatic soft tissue leiomyosarcoma 48
Palbociclib in hormone-receptor-positive advanced breast cancer 47
Three-week versus four-week schedule of cisplatin and gemcitabine: Results of a randomized phase II study 46
The evolution of surgery in non-small cell lung cancer 46
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients 45
Mutational profile of malignant pleural mesothelioma (MPM) in the phase II RAMES study 45
Phase II trial of alternating intravenous and oral vinorelbine in combination with cisplatin in advanced non-small cell lung cancer 44
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407 44
The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas 43
Short schedule of cisplatin and vinorelbine: A dose-finding study in non-small-cell lung cancer 43
Single-agent chemotherapy with vinorelbine for pretreated or metastatic squamous cell carcinoma of the esophagus 43
Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria 42
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 42
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer 42
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer 42
Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: A retrospective analysis 41
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients 41
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study 41
The impact of the SARS-CoV-2 outbreak on the psychological flexibility and behaviour of cancelling medical appointments of italian patients with pre-existing medical condition: The “impact-COVID-19 for patients” multi-centre observational study 40
Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer 40
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial 39
Italian cohort of the nivolumab EAP in squamous NSCLC: Efficacy and safety in patients with CNS metastases 39
Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial 38
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 37
Soft tissue and bone sarcomas 37
Reactions and countermeasures of medical oncologists towards the incoming COVID-19 pandemic: A whatsapp messenger-based report from the Italian college of chief medical oncologists 37
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases 34
Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study 31
Totale 5.216
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.528
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.528
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021123 0 0 0 1 66 0 7 2 3 0 44 0
2021/2022458 9 54 0 2 58 51 85 23 19 1 38 118
2022/20231.096 94 16 25 133 85 207 3 171 263 5 52 42
2023/2024363 23 131 8 9 9 56 11 20 0 2 55 39
2024/20252.155 42 325 93 76 520 318 44 88 154 280 135 80
2025/2026815 188 98 492 37 0 0 0 0 0 0 0 0
Totale 5.216